Sunovion Respiratory Development Inc. clinical trials
Acquired by Sumitomo Pharma Co., Ltd., Sep 5, 2012 · source ↗
The registry lists 10 studies whose lead sponsor is Sunovion Respiratory Development Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 10, 2021.
Before and after it joined Sumitomo Pharma Co., Ltd.
- First submitted before Sunovion Respiratory Development Inc. became part of Sumitomo Pharma Co., Ltd.
- 1
- First submitted after Sunovion Respiratory Development Inc. became part of Sumitomo Pharma Co., Ltd.
- 9
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Completed
- 10
Registry sponsor names on this page
- Sunovion Respiratory Development Inc.10 studies
Something wrong with this grouping? Tell us on the Sumitomo Pharma Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Sumitomo Pharma Co., Ltd. studies →
- A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.CompletedNCT04155047Phase 4
Sponsor listed in the registry: Sunovion Respiratory Development Inc. · First submitted after Sunovion Respiratory Development Inc. became part of Sumitomo Pharma Co., Ltd.
- Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT02512302Phase 1
Sponsor listed in the registry: Sunovion Respiratory Development Inc. · First submitted after Sunovion Respiratory Development Inc. became part of Sumitomo Pharma Co., Ltd.
- Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 StudyCompletedNCT01426009Phase 2
Sponsor listed in the registry: Sunovion Respiratory Development Inc. · First submitted before Sunovion Respiratory Development Inc. became part of Sumitomo Pharma Co., Ltd.
- Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02951312Phase 2
Sponsor listed in the registry: Sunovion Respiratory Development Inc. · First submitted after Sunovion Respiratory Development Inc. became part of Sumitomo Pharma Co., Ltd.
- A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPDCompletedNCT02038829Phase 2
Sponsor listed in the registry: Sunovion Respiratory Development Inc. · First submitted after Sunovion Respiratory Development Inc. became part of Sumitomo Pharma Co., Ltd.
- Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPDCompletedNCT02347761Phase 3
Sponsor listed in the registry: Sunovion Respiratory Development Inc. · First submitted after Sunovion Respiratory Development Inc. became part of Sumitomo Pharma Co., Ltd.
- Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)CompletedNCT02347774Phase 3
Sponsor listed in the registry: Sunovion Respiratory Development Inc. · First submitted after Sunovion Respiratory Development Inc. became part of Sumitomo Pharma Co., Ltd.
- A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPDCompletedNCT02276222Phase 3
Sponsor listed in the registry: Sunovion Respiratory Development Inc. · First submitted after Sunovion Respiratory Development Inc. became part of Sumitomo Pharma Co., Ltd.
- Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02948582Phase 2
Sponsor listed in the registry: Sunovion Respiratory Development Inc. · First submitted after Sunovion Respiratory Development Inc. became part of Sumitomo Pharma Co., Ltd.
- A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01706536Phase 2
Sponsor listed in the registry: Sunovion Respiratory Development Inc. · First submitted after Sunovion Respiratory Development Inc. became part of Sumitomo Pharma Co., Ltd.